Last reviewed · How we verify
Exparel TAP + multi-modal pain regimen
Exparel is a liposomal bupivacaine formulation that provides prolonged local anesthesia when infiltrated into surgical sites, often combined with other pain management modalities to reduce opioid requirements.
Exparel is a liposomal bupivacaine formulation that provides prolonged local anesthesia when infiltrated into surgical sites, often combined with other pain management modalities to reduce opioid requirements. Used for Infiltration anesthesia and nerve block in surgical procedures, Transversus abdominis plane (TAP) block for abdominal surgery pain management.
At a glance
| Generic name | Exparel TAP + multi-modal pain regimen |
|---|---|
| Sponsor | Pacira Pharmaceuticals, Inc |
| Drug class | Local anesthetic (liposomal formulation) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Exparel (liposomal bupivacaine) uses DepoFoam technology to encapsulate bupivacaine in lipid vesicles, enabling sustained release of the local anesthetic over 72 hours. When used as part of a transversus abdominis plane (TAP) block combined with multimodal analgesia (typically including NSAIDs, acetaminophen, and/or opioids), it provides regional anesthesia that reduces postoperative pain and opioid consumption.
Approved indications
- Infiltration anesthesia and nerve block in surgical procedures
- Transversus abdominis plane (TAP) block for abdominal surgery pain management
Common side effects
- Postoperative nausea and vomiting
- Hypotension
- Bradycardia
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: